Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1992 Mar;30(3):552–556. doi: 10.1128/jcm.30.3.552-556.1992

Serological markers of posttransfusion hepatitis C viral infection.

D S Vallari 1, B W Jett 1, H J Alter 1, L T Mimms 1, R Holzman 1, J W Shih 1
PMCID: PMC265107  PMID: 1372618

Abstract

Serological markers for hepatitis C virus (HCV) infection were measured in serial samples from 14 posttransfusion chronic non-A, non-B hepatitis patients by a semiquantitative dot blot immunoassay. The assay detected antibodies to HCV by use of recombinant proteins that represent putative HCV capsid (core), nonstructural protein 3 (NS3) (33c), and NS4 (c100) epitopes. Seroconversion to anti-HCV antibodies (anti-HCV) was detected in all patients. The average time to active antibody production detected by any of the recombinant proteins was 13.8 (range, 3.6 to 22.0) weeks posttransfusion or 4.6 (range, -4.5 to 13.4) weeks after the first biochemical marker of illness. Anti-HCV were detected earliest by the core antigen in most cases; however, the patterns of anti-HCV responses varied significantly among individuals. Overall, the addition of the core and NS3 antigens to the assay enabled the detection of the antibody response 4 to 5 weeks earlier than did the addition of the c100 antigen, the sole antigen used in current screening tests in the United States. Passively transferred antibodies were detected by at least one antigen in early posttransfusion samples from 12 patients and decayed below detectable levels for all antigens in only 2 patients. Antibodies to all three gene products were evident in the last sample from all five patients monitored for greater than 3 years from transfusion indicating the persistence of antibodies in patients with chronic illness. Our data show that the period following the onset of hepatitis during which anti-HCV are not detected by current screening assays can be greatly shortened by the detection of anti-HCV responses by a combination of core, NS3, and c100 antigens.

Full text

PDF
552

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter H. J., Purcell R. H., Shih J. W., Melpolder J. C., Houghton M., Choo Q. L., Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989 Nov 30;321(22):1494–1500. doi: 10.1056/NEJM198911303212202. [DOI] [PubMed] [Google Scholar]
  2. Bolling T. J., Mandecki W. An Escherichia coli expression vector for high-level production of heterologous proteins in fusion with CMP-KDO synthetase. Biotechniques. 1990 May;8(5):488–492. [PubMed] [Google Scholar]
  3. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  4. Choo Q. L., Richman K. H., Han J. H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby R., Barr P. J. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2451–2455. doi: 10.1073/pnas.88.6.2451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Donohue J., Bailey M., Gray R., Holen J., Huang T. M., Keevan J., Mattimiro C., Putterman C., Stalder A., Defreese J. Enzyme immunoassay system for panel testing. Clin Chem. 1989 Sep;35(9):1874–1877. [PubMed] [Google Scholar]
  6. Esteban J. I., Esteban R., Viladomiu L., López-Talavera J. C., González A., Hernández J. M., Roget M., Vargas V., Genescà J., Buti M. Hepatitis C virus antibodies among risk groups in Spain. Lancet. 1989 Aug 5;2(8658):294–297. doi: 10.1016/s0140-6736(89)90485-6. [DOI] [PubMed] [Google Scholar]
  7. Esteban J. I., González A., Hernández J. M., Viladomiu L., Sánchez C., López-Talavera J. C., Lucea D., Martin-Vega C., Vidal X., Esteban R. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med. 1990 Oct 18;323(16):1107–1112. doi: 10.1056/NEJM199010183231605. [DOI] [PubMed] [Google Scholar]
  8. Houghton M., Weiner A., Han J., Kuo G., Choo Q. L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991 Aug;14(2):381–388. [PubMed] [Google Scholar]
  9. Kuo G., Choo Q. L., Alter H. J., Gitnick G. L., Redeker A. G., Purcell R. H., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 Apr 21;244(4902):362–364. doi: 10.1126/science.2496467. [DOI] [PubMed] [Google Scholar]
  10. Mimms L., Vallari D., Ducharme L., Holland P., Kuramoto I. K., Zeldis J. Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions. Lancet. 1990 Dec 22;336(8730):1590–1591. doi: 10.1016/0140-6736(90)93377-2. [DOI] [PubMed] [Google Scholar]
  11. Miyamura T., Saito I., Katayama T., Kikuchi S., Tateda A., Houghton M., Choo Q. L., Kuo G. Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A. 1990 Feb;87(3):983–987. doi: 10.1073/pnas.87.3.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Shimizu Y. K., Weiner A. J., Rosenblatt J., Wong D. C., Shapiro M., Popkin T., Houghton M., Alter H. J., Purcell R. H. Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6441–6444. doi: 10.1073/pnas.87.16.6441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Weiner A. J., Truett M. A., Rosenblatt J., Han J., Quan S., Polito A. J., Kuo G., Choo Q. L., Houghton M., Agius C. HCV testing in low-risk population. Lancet. 1990 Sep 15;336(8716):695–695. doi: 10.1016/0140-6736(90)92194-m. [DOI] [PubMed] [Google Scholar]
  14. Zachoval R., Jilg W., Lorbeer B., Schmidt M., Deinhardt F. Passive/active immunization against hepatitis B. J Infect Dis. 1984 Jul;150(1):112–117. doi: 10.1093/infdis/150.1.112. [DOI] [PubMed] [Google Scholar]
  15. van der Poel C. L., Reesink H. W., Lelie P. N., Leentvaar-Kuypers A., Choo Q. L., Kuo G., Houghton M. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. Lancet. 1989 Aug 5;2(8658):297–298. doi: 10.1016/s0140-6736(89)90486-8. [DOI] [PubMed] [Google Scholar]
  16. van der Poel C. L., Reesink H. W., Schaasberg W., Leentvaar-Kuypers A., Bakker E., Exel-Oehlers P. J., Lelie P. N. Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet. 1990 Mar 10;335(8689):558–560. doi: 10.1016/0140-6736(90)90347-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES